Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer Article

Industry Collaboration

cited authors

  • Patel, Jyoti D.; Bonomi, Philip; Socinski, Mark A.; Govindan, Ramaswamy; Hong, Shengyan; Obasaju, Coleman; Pennella, Eduardo J.; Girvan, Allicia C.; Guba, Susan C.

authors

Publication Date

  • July 1, 2009

webpage

published in

category

keywords

  • Antifolate
  • Biomarkers
  • Induction therapy
  • Maintenance therapy

start page

  • 252

end page

  • 256

volume

  • 10

issue

  • 4